Silo Pharma (NASDAQ:SILO – Get Free Report) and Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
Earnings & Valuation
This table compares Silo Pharma and Arcutis Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silo Pharma | $54,077.00 | 54.09 | -$4.23 million | ($4.36) | -0.42 |
| Arcutis Biotherapeutics | $508.68 million | 7.06 | -$16.14 million | $0.21 | 135.14 |
Institutional & Insider Ownership
5.6% of Silo Pharma shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Silo Pharma and Arcutis Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
| Arcutis Biotherapeutics | 5.88% | 14.18% | 6.28% |
Risk & Volatility
Silo Pharma has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Silo Pharma and Arcutis Biotherapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Arcutis Biotherapeutics | 0 | 2 | 8 | 0 | 2.80 |
Arcutis Biotherapeutics has a consensus target price of $39.75, indicating a potential upside of 40.06%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Silo Pharma.
Summary
Arcutis Biotherapeutics beats Silo Pharma on 11 of the 14 factors compared between the two stocks.
About Silo Pharma
Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
